Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling…
Month: August 2023
Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal…
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into…
Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first…
Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first…
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions…
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions…
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late…
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late…
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
Sub-group analyses of patients with early Parkinson’s disease (PD) at different age groups or baseline…
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
Sub-group analyses of patients with early Parkinson’s disease (PD) at different age groups or baseline…
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage…
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage…
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company)…